keyword
MENU ▼
Read by QxMD icon Read
search

Tenofovir

keyword
https://www.readbyqxmd.com/read/28101146/bone-health-in-hiv-and-hepatitis-b-or-c-infections
#1
REVIEW
Emmanuel Biver, Alexandra Calmy, René Rizzoli
Chronic infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) add to age-dependent bone loss and may contribute to lower bone strength in the elderly. In this review, we report recent highlights on the epidemiology of bone fragility in chronic viral infections with HIV, HCV and HBV, its physiopathology and discuss the interference of antiviral therapies with bone metabolism. Chronic infections influence bone through the interactions between risk factors for bone fragility and falls (which are highly prevalent in infected patients), virus activity and antiviral drugs...
January 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28099191/long-acting-combination-anti-hiv-drug-suspension-enhances-and-sustains-higher-drug-levels-in-lymph-node-cells-than-in-blood-cells-and-plasma
#2
John C Kraft, Lisa A McConnachie, Josefin Koehn, Loren Kinman, Carol Collins, Danny D Shen, Ann C Collier, Rodney J Y Ho
OBJECTIVE: To determine if a combination of anti-HIV drugs-tenofovir (TFV), lopinavir (LPV), and ritonavir (RTV)-in a lipid-stabilized nanosuspension (called TLC-ART101) could enhance and sustain intracellular drug levels and exposures in lymph node and blood cells above those in plasma. DESIGN: Four macaques were given a single dose of TLC-ART101 subcutaneously. Drug concentrations in plasma and mononuclear cells of the blood (PBMCs) and lymph nodes (LNMCs) were analyzed using a validated combination LC-MS/MS assay...
January 17, 2017: AIDS
https://www.readbyqxmd.com/read/28099188/hepatitis-b-incidence-and-prevention-with-antiretroviral-therapy-among-hiv-positive-individuals-in-rakai-uganda
#3
Emmanuel Seremba, Victor Ssempijja, Sarah Kalibbala, Ronald H Gray, Maria J Wawer, Fred Nalugoda, Corey Casper, Warren T Phipps, Ponsiano Ocama, David Serwadda, David L Thomas, Steven Reynolds
OBJECTIVE: Antiretroviral therapy (ART) may interfere with replication of hepatitis B (HBV) raising the hypothesis that HBV infection might be prevented by ART. We investigated the incidence and risk factors associated with HBV among HIV-infected adults in Rakai, Uganda. METHODS: We screened stored sera from 944 HIV-infected adults enrolled in the Rakai Community Cohort Study between September 2003 and March 2015 for evidence of HBV exposure. Serum from participants who tested anti-HBc negative (497) at baseline were tested over 3-7 consecutive survey rounds for incident HBV...
January 17, 2017: AIDS
https://www.readbyqxmd.com/read/28094565/the-decline-in-hiv-1-drug-resistance-in-heavily-antiretroviral-experienced-patients-is-associated-with-optimized-prescriptions-in-a-treatment-roll-out-program-in-mexico
#4
Juan J Calva, Silvana Larrea, Marco A Tapia-Maltos, Mauricio Ostrosky-Frid, Carolina Lara, Pedro Aguilar-Salinas, Héctor Rivera, Juan P Ramírez
A decrease in the rate of acquired antiretroviral (ARV) drug-resistance (ADR) over time has been documented in high-income settings, but data on the determinants of this phenomenon are lacking. We tested the hypothesis that in heavily ARV-experienced patients in the Mexican ARV therapy (ART) roll-out program, the drop in ADR would be associated with changes in ARV drug usage. Genotypic resistance tests obtained from 974 HIV-infected patients with virologic failure and at least 2 previously failed ARV regimens from throughout the country were analyzed for the presence of nRTI, NNRTI and PI resistance-associated mutations (RAMs)...
January 17, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28091393/viral-blips-were-infrequent-in-treatment-naive-adults-treated-with-rilpivirine-emtricitabine-tenofovir-df-or-efavirenz-emtricitabine-tenofovir-df-through-96-weeks
#5
Danielle P Porter, Rima Kulkarni, Will Garner, Michael D Miller, Kirsten L White
BACKGROUND: The clinical impact of transient episodes of HIV viremia (viral blips) on virologic failure and resistance development is not fully understood. Here we investigated the blip frequency and virologic outcomes of HIV-1-infected subjects experiencing viral blips among treatment-naïve subjects initiating therapy on rilpivirine (RPV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF through 96 weeks of treatment. METHODS: Subjects treated with at least one dose of study drug and with at least one post-baseline HIV-1 RNA value were included in this analysis...
January 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28087953/tenofovir-induced-nephrotoxicity-a-retrospective-cohort-study
#6
H M Koh, K Suresh
BACKGROUND: Tenofovir (TDF) has been associated with renal function deterioration, but local data regarding the incidence and risk factors for this adverse event were lacking. OBJECTIVES: To determine the incidence of nephrotoxicity in HIV-infected patients on tenofovir-based regimens and to evaluate risk factors involved in tenofovir-associated renal function decline. METHODS: This is a single-centre retrospective cohort study of 440 HIV-infected adults who were started on tenofovirbased antiretroviral regimens...
December 2016: Medical Journal of Malaysia
https://www.readbyqxmd.com/read/28081595/switch-to-tenofovir-based-therapy-or-to-continue-adefovir-based-therapy-in-chb-patients-with-suboptimal-response-to-adefovir-based-combination
#7
Byung-Cheol Song
No abstract text is available yet for this article.
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28078526/effectiveness-and-safety-of-entecavir-or-tenofovir-in-a-spanish-cohort-of-chronic-hepatitis-b-patients-validation-of-the-page-b-score-to-predict-hepatocellular-carcinoma
#8
Mar Riveiro-Barciela, David Tabernero, José L Calleja, Sabela Lens, María L Manzano, Francisco Gea Rodríguez, Javier Crespo, Belén Piqueras, Juan M Pascasio, Carmen Comas, Maria L Gutierrez, Alberto Aguirre, Emilio Suárez, Javier García-Samaniego, Miguel Rivero, Doroteo Acero, Miguel Fernandez-Bermejo, Diego Moreno, Pilar Sánchez-Pobre, Beatriz de Cuenca, J J Moreno-Palomares, Rafael Esteban, Maria Buti
BACKGROUND: Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. AIMS: To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. METHODS: Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP...
January 11, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28076335/infrequent-development-of-drug-resistance-in-hiv-1-infected-treatment-naive-subjects-after-96-weeks-of-treatment-with-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-or-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate
#9
Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D Miller, Christian Callebaut
BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide RT inhibitor (NtRTI) tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF). The single-tablet regimen (STR) composed of elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) has demonstrated non-inferiority to the STR of E/C/F/TDF in clinical studies, with high proportions of subjects achieving HIV-1 RNA <50 copies/mL at week 48, and maintained through week 96...
January 11, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28073964/single-dose-pharmacokinetics-and-pharmacodynamics-of-oral-tenofovir-and-emtricitabine-in-blood-saliva-and-rectal-tissue-a-sub-study-of-the-anrs-ipergay-trial
#10
Julien Fonsart, Sentob Saragosti, Milad Taouk, Gilles Peytavin, Lane Bushman, Isabelle Charreau, Allan Hance, Lauriane Goldwirt, Stéphane Morel, Fabrizio Mammano, Bénédicte Loze, Catherine Capitant, François Clavel, Nadia Mahjoub, Laurence Meyer, Peter L Anderson, Constance Delaugerre, Jean-Michel Molina
OBJECTIVES: In the ANRS IPERGAY pre-exposure prophylaxis (PrEP) trial, a single dose of tenofovir disoproxil fumarate and emtricitabine was taken orally 2-24 h before sexual intercourse. A sub-study was conducted to assess the pharmacokinetics of tenofovir and emtricitabine in blood, saliva and rectal tissue following this initial oral intake. METHODS: Plasma, PBMC, saliva and rectal tissue sampling was performed over 24 h in 12 seronegative men before enrolment in the ANRS IPERGAY trial, following a single dose of 600 mg tenofovir disoproxil fumarate/400 mg emtricitabine...
September 28, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28073073/development-and-validation-of-a-liquid-chromatography-ms-ms-method-for-simultaneous-quantification-of-tenofovir-and-efavirenz-in-biological-tissues-and-fluids
#11
Luisa Barreiros, Cassilda Cunha-Reis, Eduarda M P Silva, Joana R B Carvalho, José das Neves, Bruno Sarmento, Marcela A Segundo
Millions of people worldwide live with human immunodeficiency virus (HIV) infection thus justifying the continuous search for new prevention and treatment strategies, including topical microbicide products combining antiretroviral drugs (ARVs) such as tenofovir (TFV) and efavirenz (EFV). Therefore, the aim of this work was to develop and validate a high performance liquid chromatography method coupled to triple quadrupole-tandem mass spectrometry (HPLC-MS/MS) for the quantification of TFV and EFV in biological matrices (mouse vaginal tissue, vaginal lavage and blood plasma)...
December 27, 2016: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/28067119/efficacy-and-safety-of-unboosting-atazanavir-in-a-randomized-controlled-trial-among-hiv-infected-patients-receiving-tenofovir-df
#12
Marianne Harris, Bruce Ganase, Birgit Watson, Mark W Hull, Silvia A Guillemi, Wendy Zhang, Ramesh Saeedi, P Richard Harrigan
OBJECTIVES: To assess safety and efficacy of a switch to unboosted atazanavir (ATV) among HIV-infected adults receiving ATV/ritonavir (r) and tenofovir disoproxil fumarate (TDF). METHODS: HIV-infected adults with viral load (VL) <40 copies/mL at screening and <150 copies/mL consistently for ≥3 months while receiving a regimen including ATV/r and TDF were randomized to continue ATV/r 300/100 mg daily (control) or change to ATV 400 mg daily (switch), while maintaining their TDF backbone...
January 9, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28065890/impact-of-obesity-on-antiretroviral-pharmacokinetics-and-immuno-virological-response-in-hiv-infected-patients-a-case-control-study
#13
Vincent Madelain, Minh P Le, Karen Champenois, Charlotte Charpentier, Roland Landman, Veronique Joly, Patrick Yeni, Diane Descamps, Yazdan Yazdanpanah, Gilles Peytavin
BACKGROUND: Obesity has high prevalence among HIV-infected patients. Increased adipose tissue mass affects the pharmacokinetics of numerous drugs, but few data are available for antiretroviral drugs. OBJECTIVES: In this study we aimed to explore the pharmacokinetics of antiretroviral drugs and the immuno-virological response in obese patients with HIV infection. PATIENTS AND METHODS: We examined data from 2009 to 2012 in our hospital's database for HIV-1-infected patients who received an antiretroviral drug (abacavir, emtricitabine, lamivudine, tenofovir, efavirenz, etravirine, nevirapine, atazanavir/ritonavir, darunavir/ritonavir, lopinavir/ritonavir or raltegravir)...
January 8, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28064418/novel-antiretroviral-drugs-in-patients-with-renal-impairment-clinical-and-pharmacokinetic-considerations
#14
Dario Cattaneo, Cristina Gervasoni
Highly active antiretroviral therapy (HAART) has dramatically increased the survival of HIV-infected patients from Western countries reducing the incidence of opportunistic infections and AIDS-related malignancies, and improving the patients' quality of life compared with the pre-HAART era. HIV is thus now considered in the West as a chronic disease, with the majority of HIV-infected patients successfully reaching an optimal immune and virological outcome a few months after starting HAART. However, this switch from acute to chronic disease has been accompanied by an increased incidence of chronic kidney disease (CKD), reported in up to 60% of HIV-infected patients...
January 7, 2017: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/28063964/impact-of-hepatitis-b-core-antibody-hbcab-seropositivity-on-the-outcome-of-autologous-hematopoietic-stem-cell-transplantation-for-multiple-myeloma
#15
Ankur Varma, Laura Biritxinaga, Rima M Saliba, Maximilian Stich, Sarah Francesca Jauch, Aimaz Afrough, Medhavi Honhar, Uday R Popat, Mehnaz A Shafi, Nina Shah, Qaiser Bashir, Yvonne Dinh, Chitra Hosing, Richard E Champlin, Muzaffar H Qazilbash
Hepatitis B core antibody (HBcAb) seropositivity has been associated with a higher rate of hepatitis B virus (HBV) reactivation after chemotherapy, even in patients who are hepatitis B surface antigen (HBsAg) negative. However, little is known about the risk of HBV reactivation after autologous hematopoietic stem cell transplantation (auto-HCT). We evaluated the incidence of HBV reactivation, liver toxicity and survival in patients with multiple myeloma (MM) who received auto-HCT at our institution. We retrospectively identified 107 MM patients with resolved HBV infection (HBcAb positive, HBsAg negative) and 125 patients with negative HBV serology (controls) who were matched for age, timing of auto-HCT from diagnosis, cytogenetics, disease status at transplant, induction therapy, and preparative regimen...
January 4, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28061820/associations-of-statins-and-antiretroviral-drugs-with-the-onset-of-type-2-diabetes-among-hiv-1-infected-patients
#16
Vincenzo Spagnuolo, Laura Galli, Andrea Poli, Stefania Salpietro, Nicola Gianotti, Piermarco Piatti, Francesca Cossarini, Concetta Vinci, Elisabetta Carini, Adriano Lazzarin, Antonella Castagna
BACKGROUND: Statin use is associated with a modest increase in the incidence of type 2 diabetes mellitus (DM) among the general population. However, HIV-infected patients have a higher risk of developing DM, and it is unclear whether statins have a diabetogenic effect in these patients. Therefore, we investigated the associations of statin use and exposure to antiretroviral drugs with type 2 DM onset in a cohort of HIV-infected patients. METHODS: This retrospective, controlled, cohort study identified HIV-1-infected patients who did not have DM and were not receiving statins at their antiretroviral treatment (ART) initiation...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28060011/topical-tenofovir-protects-against-vaginal-shiv-infection-in-macaques-co-infected-with-chlamydia-trachomatis-and-trichomonas-vaginalis
#17
Natalia Makarova, Tara Henning, Andrew Taylor, Chuong Dinh, Jonathan Lipscomb, Rachael Aubert, Debra Hanson, Christi Phillips, John Papp, James Mitchell, Janet Mcnicholl, Gerardo J Garcia-Lerma, Walid Heneine, Ellen Kersh, Charles Dobard
BACKGROUND: Chlamydia trachomatis (CT) and Trichomonas vaginalis (TV), two prevalent sexual transmitted infections, are known to increase HIV risk in women and could potentially diminish pre-exposure prophylaxis (PrEP) efficacy, particularly for topical interventions that rely on local protection. We investigated in macaques whether co-infection with CT/TV reduces protection by vaginal TFV gel. METHODS: Vaginal TFV gel dosing previously shown to provide 100% or 74% protection when applied either 30 minutes or 3 days before SHIV challenge was assessed in pigtailed macaques co-infected with CT/TV and challenged twice-weekly with SHIV162p3 for up to 10 weeks (2 menstrual cycles)...
January 4, 2017: AIDS
https://www.readbyqxmd.com/read/28060010/predictors-of-longitudinal-change-in-bone-mineral-density-in-a-cohort-of-hiv-positive-and-negative-subjects
#18
Willard Tinago, Aoife G Cotter, Caroline Sabin, Alan Macken, Eoin Kavanagh, Jennifer Brady, Geraldine McCarthy, Juliet Compston, Patrick W G Mallon
OBJECTIVE: Although low bone mineral density (BMD) is prevalent in HIV, changes in BMD over time remain unclear. We aimed to compare rates of, and factors associated with, BMD change between HIV-positive and HIV-negative subjects. METHODS: In a prospective, 3-year cohort, HIV-positive and HIV-negative subjects provided annual demographic and clinical data, fasting bloods and dual x-ray absorptiometry (DXA). Using longitudinal mixed models we compared and determined predictors of rate of change in BMD...
January 4, 2017: AIDS
https://www.readbyqxmd.com/read/28054933/association-of-hiv-infection-with-biomarkers-of-kidney-injury-and-fibrosis-in-the-multicenter-aids-cohort-study
#19
Vasantha Jotwani, Rebecca Scherzer, Michelle M Estrella, Lisa P Jacobson, Mallory D Witt, Frank Palella, Ken Ho, Michael Bennett, Chirag R Parikh, Joachim H Ix, Michael Shlipak
BACKGROUND: Chronic kidney disease (CKD) is common among HIV-infected individuals, but serum creatinine is insensitive for detecting kidney damage at early stages. We hypothesized that HIV infection would be associated with elevations in subclinical markers of kidney injury and fibrosis in a contemporary cohort of men. METHODS: In this cross-sectional study, we measured urine levels of interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), pro-collagen type III N-terminal pro-peptide (PIIINP), and albumin-creatinine ratio (ACR) in 813 HIV-infected and 331 uninfected men enrolled in the Multicenter AIDS Cohort Study...
January 5, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28052621/hepatitis-b-virus-long-term-impact-of-antiviral-therapy-nucleot-s-ide-analogues-nucs
#20
REVIEW
Glenda Grossi, Mauro Viganò, Alessandro Loglio, Pietro Lampertico
The goal of antiviral therapy is to improve the quality of life and survival of patients with chronic hepatitis B (CHB) by halting the progression to cirrhosis, end-stage liver disease or hepatocellular carcinoma (HCC), thus preventing anticipated liver-related death. Oral administration of potent and less resistance-prone nucleot(s)ide analogues (NUCs), such as entecavir (ETV) and tenofovir disoproxil fumarate (TDF) has become the most popular treatment strategy worldwide because of their excellent efficacy and safety profile as well as easy management confirmed in both registration trials and in clinical practice studies...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
2109
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"